Cargando…
GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition
Melanoma is an aggressive skin cancer that has become increasingly prevalent in western populations. Current treatments such as surgery, chemotherapy, and high-dose radiation have had limited success, often failing to treat late stage, metastatic melanoma. Alternative strategies such as immunotherap...
Autores principales: | Hathaway-Schrader, Jessica D., Norton, Duncan, Hastings, Katherine, Doonan, Bently P., Fritz, Shaun Tompkins, Bethard, Jennifer R., Blum, Janice S., Haque, Azizul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835040/ https://www.ncbi.nlm.nih.gov/pubmed/35162988 http://dx.doi.org/10.3390/ijms23031066 |
Ejemplares similares
-
Peptide Modification Diminishes HLA Class II-restricted CD4(+) T Cell Recognition of Prostate Cancer Cells
por: Doonan, Bently P., et al.
Publicado: (2022) -
Insights into the Role of GILT in HLA Class II Antigen Processing and Presentation by Melanoma
por: Norton, Duncan L., et al.
Publicado: (2009) -
Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design
por: Doonan, Bently P, et al.
Publicado: (2015) -
HLA Class II Defects in Burkitt Lymphoma: Bryostatin-1-Induced 17 kDa Protein Restores CD4+ T-Cell Recognition
por: Hossain, Azim, et al.
Publicado: (2011) -
Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma
por: God, Jason M., et al.
Publicado: (2016)